Annovis Bio, Inc.
NYQ: ANVSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Annovis Bio, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ANVS Z-Score →About Annovis Bio, Inc.
Healthcare
Biotechnology
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
📊 Fundamental Analysis
Annovis Bio, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -220.6%, which indicates that capital utilization is currently under pressure.
At a current price of $1.59, ANVS currently trades near the bottom of its 52-week range (9%), indicating potential value or weakness (Range: $1.19 - $5.50).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$46.54M
Trailing P/E
--
Forward P/E
-1.47
Beta (5Y)
1.36
52W High
$5.50
52W Low
$1.19
Avg Volume
588K
Day High
Day Low